Cargando…
Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix
When compared with biological samples in other matrices (plasma, urine, etc.) that are typically seen in bioanalytical applications, whole blood samples present unique challenges in method development, because of the viscous nature of blood and complexity of its constituents. In this article, we hav...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986713/ https://www.ncbi.nlm.nih.gov/pubmed/27721348 http://dx.doi.org/10.3390/pharmaceutics2020159 |
_version_ | 1782311760120774656 |
---|---|
author | Xu, Raymond N. Polzin, Jill Kranz, Michelle Vaca, Phillip Metchkarova, Maria Rieser, Matthew J. El-Shourbagy, Tawakol A. |
author_facet | Xu, Raymond N. Polzin, Jill Kranz, Michelle Vaca, Phillip Metchkarova, Maria Rieser, Matthew J. El-Shourbagy, Tawakol A. |
author_sort | Xu, Raymond N. |
collection | PubMed |
description | When compared with biological samples in other matrices (plasma, urine, etc.) that are typically seen in bioanalytical applications, whole blood samples present unique challenges in method development, because of the viscous nature of blood and complexity of its constituents. In this article, we have developed and validated a series of quantitative bioanalytical methods for the determination of a pharmaceutical compound, Compound A, and its phosphate metabolite from whole blood matrices using liquid chromatography tandem mass spectrometry. All methods employed a simple protein precipitation procedure that was automated in 96-well format. The methods were subjected to vigorous tests in precision, accuracy, matrix effect, reproducibility, and robustness. Monolithic chromatography was used to improve sample throughput in one of the methods. The results also demonstrated that proper sample preparation procedures, such as sample transfer and lysing of blood cells prior to the extraction, are key to reproducible results for pharmacokinetic parameter determination. |
format | Online Article Text |
id | pubmed-3986713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-39867132014-04-15 Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix Xu, Raymond N. Polzin, Jill Kranz, Michelle Vaca, Phillip Metchkarova, Maria Rieser, Matthew J. El-Shourbagy, Tawakol A. Pharmaceutics Article When compared with biological samples in other matrices (plasma, urine, etc.) that are typically seen in bioanalytical applications, whole blood samples present unique challenges in method development, because of the viscous nature of blood and complexity of its constituents. In this article, we have developed and validated a series of quantitative bioanalytical methods for the determination of a pharmaceutical compound, Compound A, and its phosphate metabolite from whole blood matrices using liquid chromatography tandem mass spectrometry. All methods employed a simple protein precipitation procedure that was automated in 96-well format. The methods were subjected to vigorous tests in precision, accuracy, matrix effect, reproducibility, and robustness. Monolithic chromatography was used to improve sample throughput in one of the methods. The results also demonstrated that proper sample preparation procedures, such as sample transfer and lysing of blood cells prior to the extraction, are key to reproducible results for pharmacokinetic parameter determination. MDPI 2010-04-30 /pmc/articles/PMC3986713/ /pubmed/27721348 http://dx.doi.org/10.3390/pharmaceutics2020159 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Xu, Raymond N. Polzin, Jill Kranz, Michelle Vaca, Phillip Metchkarova, Maria Rieser, Matthew J. El-Shourbagy, Tawakol A. Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title | Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title_full | Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title_fullStr | Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title_full_unstemmed | Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title_short | Strategies for Developing Sensitive and Automated LC-MS/MS Assays of a Pharmaceutical Compound and Its Metabolite from Whole Blood Matrix |
title_sort | strategies for developing sensitive and automated lc-ms/ms assays of a pharmaceutical compound and its metabolite from whole blood matrix |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986713/ https://www.ncbi.nlm.nih.gov/pubmed/27721348 http://dx.doi.org/10.3390/pharmaceutics2020159 |
work_keys_str_mv | AT xuraymondn strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT polzinjill strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT kranzmichelle strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT vacaphillip strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT metchkarovamaria strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT riesermatthewj strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix AT elshourbagytawakola strategiesfordevelopingsensitiveandautomatedlcmsmsassaysofapharmaceuticalcompoundanditsmetabolitefromwholebloodmatrix |